Welcome to our dedicated page for Coherus news (Ticker: CHRS), a resource for investors and traders seeking the latest updates and insights on Coherus stock.
Coherus Oncology, Inc. (NASDAQ: CHRS) is a commercial-stage oncology company whose news flow is centered on its PD-1 inhibitor LOQTORZI (toripalimab-tpzi) and a proprietary immuno-oncology pipeline. Company announcements frequently highlight clinical data, regulatory developments, financial results and strategic updates related to its antibody-based cancer therapies.
News about Coherus Oncology often covers LOQTORZI in nasopharyngeal carcinoma (NPC), including long-term survival data from the JUPITER-02 Phase 3 trial evaluating LOQTORZI plus chemotherapy in recurrent or metastatic NPC. Releases also describe LOQTORZI’s approved indications in the United States and its role as the only FDA-approved and available treatment for recurrent, locally advanced or metastatic NPC across all patient subsets and lines of therapy.
Investors and clinicians following CHRS can expect regular updates on pipeline programs such as CHS-114 and casdozokitug. Coherus reports biomarker and proof-of-mechanism data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, in head and neck squamous cell carcinoma and other solid tumors, as well as clinical and translational findings for casdozokitug, a novel IL-27 antagonist in advanced solid tumors including hepatocellular carcinoma and non-small cell lung cancer.
The company’s news stream also includes quarterly financial results, business updates, participation in major healthcare and oncology conferences, and investor-focused events. These items provide context on revenue trends for LOQTORZI, research and development spending on its immuno-oncology programs, and corporate strategy.
For market participants tracking CHRS, the Coherus Oncology news page on Stock Titan aggregates these press releases and related coverage, offering a centralized view of clinical milestones, regulatory disclosures and financial communications that can influence perceptions of the company’s oncology franchise and pipeline progress.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On April 27, 2023, Coherus BioSciences (Nasdaq: CHRS) and Junshi Biosciences announced that data from four pivotal clinical studies of toripalimab will be presented at the ASCO Annual Meeting from June 2-6, 2023. Key presentations include final overall survival analyses from phase 3 studies for nasopharyngeal carcinoma and non-small cell lung cancer, and interim analyses for resectable stage cancers. The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for advanced recurrent nasopharyngeal carcinoma. This demonstrates the potential of toripalimab, an anti-PD-1 monoclonal antibody, in treating multiple cancer types, with ongoing studies covering over 15 indications globally.